Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)

被引：0
|
作者：
Storniolo, A. [1 ]
Koehler, M. [2 ]
Preston, A. [2 ]
Rappold, E. [2 ]
Byrne, J. [2 ]
Stein, S. [2 ]
Ewer, M. [3 ]
机构：
[1] Indiana Univ, Med Ctr, Indianapolis, IN USA
[2] GlaxoSmithKline Inc, Oncol Med Dev Ctr, Collegeville, PA USA
[3] MD Anderson Canc Ctr, Houston, TX USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70771-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [31] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [32] A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
    Lim, Bora
    Murthy, Rashmi K.
    Lee, Jangsoon
    Jackson, Summer A.
    Lwase, Toshiaki
    Davis, Darren W.
    Willey, Jie S.
    Wu, Jimin
    Shen, Yu
    Tripathy, Debu
    Alvarez, Ricardo
    Ibrahim, Nuhad K.
    Brewster, Abenaa M.
    Barcenas, Carlos H.
    Brown, Powel H.
    Giordano, Sharon H.
    Moulder, Stacy L.
    Booser, Daniel J.
    Moscow, Jeffrey A.
    Piekarz, Richard
    Valero, Vicente
    Ueno, Naoto T.
    BRITISH JOURNAL OF CANCER, 2019, 120 (12) : 1105 - 1112
  • [33] A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
    Bora Lim
    Rashmi K. Murthy
    Jangsoon Lee
    Summer A. Jackson
    Toshiaki Iwase
    Darren W. Davis
    Jie S. Willey
    Jimin Wu
    Yu Shen
    Debu Tripathy
    Ricardo Alvarez
    Nuhad K. Ibrahim
    Abenaa M. Brewster
    Carlos H. Barcenas
    Powel H. Brown
    Sharon H. Giordano
    Stacy L. Moulder
    Daniel J. Booser
    Jeffrey A. Moscow
    Richard Piekarz
    Vicente Valero
    Naoto T. Ueno
    British Journal of Cancer, 2019, 120 : 1105 - 1112
  • [34] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Li, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [35] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (PTS) with HER2-positive metastatic breast cancer (MBC)
    Xu, Ligong
    Song, Santai
    Zhu, Jianxin
    Luo, Rongcheng
    Li, Lejing
    Jiao, Sunchang
    Chen, Li
    Tao, Min
    Su, Yongqian
    Liu, Duanqi
    ANNALS OF ONCOLOGY, 2006, 17 : 76 - 77
  • [36] Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial.
    Modi, S.
    Stopeck, A.
    Kinden, H.
    Sugarman, S.
    Ma, W.
    Solit, D.
    Kersey, K.
    Johnson, R.
    Hannah, A. L.
    Hudis, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S269 - S270
  • [37] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    V Guarneri
    A Frassoldati
    F Piacentini
    K Cagossi
    L Cavanna
    A Michelotti
    G Jovic
    S Giovannelli
    G Ficarra
    C Oliva
    P Conte
    Breast Cancer Research, 9
  • [38] Phase II Evaluation of a Novel Capecitabine Schedule in Combination with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab
    Gajria, D.
    Theodoulou, M.
    Feigin, K.
    Patil, S.
    Geneus, S.
    Drullinsky, P.
    D'Andrea, G.
    Lake, D.
    Norton, L.
    Hudis, C.
    Traina, T. A.
    CANCER RESEARCH, 2009, 69 (24) : 803S - 803S
  • [39] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    Guarneri, V.
    Frassoldati, A.
    Piacentini, F.
    Cagossi, K.
    Cavanna, L.
    Michelotti, A.
    Jovic, G.
    Giovannelli, S.
    Ficarra, G.
    Oliva, C.
    Conte, P.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [40] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345